Iterum Therapeutics plc
Company Information
Industry Pharmaceutical Preparations
SIC Code 2834
Entity Type operating
SEC Category Non-accelerated filerSmaller reporting company
State of Incorporation Ireland
Business Address 3 DUBLIN LANDINGS, DUBLIN 1, L2, D01 H104
Mailing Address 3 DUBLIN LANDINGS, DUBLIN 1, L2, D01 H104
Phone (872) 225-6077
Fiscal Year End 1231
EIN 000000000
Financial Overview
FY2024
-$24.77M
Net Income
$-1.26
EPS
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| DEF 14A Definitive proxy statement | January 2, 2026 | View on SEC |
| 8-K Current report of material events | December 12, 2025 | View on SEC |
| 4 Insider stock transaction report | November 20, 2025 | View on SEC |
| 8-K Current report of material events | November 14, 2025 | View on SEC |
| 10-Q Quarterly financial report | November 14, 2025 | View on SEC |
| 8-K Current report of material events | October 16, 2025 | View on SEC |
| 424B5 Prospectus supplement | October 16, 2025 | View on SEC |
| 8-K Current report of material events | September 10, 2025 | View on SEC |
| 8-K Current report of material events | August 28, 2025 | View on SEC |
| 8-K Current report of material events | August 20, 2025 | View on SEC |
Material Events
8-K Financial Distress December 12, 2025
High Impact
- Iterum Therapeutics received a Complete Response Letter (CRL) from the U.S. FDA for its antibiotic, sulopenem, indicating a delay in approval due to requests for more information/changes.
- Nasdaq notified Iterum that its stock no longer meets several key listing requirements, including minimum market value and share price, threatening potential delisting.
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.